SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab plus talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC)

被引：0
|
作者：
Abdel Karim, Nagla Fawzy
Miao, Jieling
Reckamp, Karen L.
Michael Gay, Carl
Averett Byers, Lauren
Zhao, Yingqi
Weber Redman, Mary
Carrizosa, Daniel R.
Wang, Wei-Lien
Petty, William J.
Mehta, Kathan
Faller, Bryan A.
Agamah, Edem S.
Kasbari, Samer S.
Katipamula Malisetti, Rajini
Kumar, Atul
Schallenkamp, John
Chaitanya Alluri, Krishna
Elaine Gray, Jhanelle
Kelly, Karen
机构：
[1] Univ Virginia, Inova Schar Canc Inst, Fairfax, VA USA
[2] SWOG Stat Ctr, Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[3] Cedars Sinai Med Ctr, Los Angeles, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[6] SWOG Stat & Data Management Ctr, Fred Hutchinson Canc Ctr, Seattle, WA USA
[7] Levine Canc Inst, Charlotte, NC USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX USA
[9] Wake Forest Coll, Winston Salem, NC USA
[10] Missouri Baptist Med Ctr, St Loius, MO USA
[11] Southern Illinois Univ, Springfield, IL USA
[12] Southeastern Med Oncol Ctr, Goldsboro, NC USA
[13] Minnesota Oncol Hematol, Coon Rapids, MN USA
[14] Univ New Mexico Comprehens Canc Ctr, Albuquerque, NM USA
[15] Billings Clin, Billings, MT USA
[16] St Lukes Canc Inst, Boise, ID USA
[17] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[18] UC Davis Comprehens Canc Ctr, Sacramento, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8504
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929
    Karim, Nagla Abdel
    Miao, Jieling
    Reckamp, Karen L.
    Gay, Carl M.
    Byers, Lauren A.
    Zhao, Ying-Qi
    Redman, Mary W.
    Carrizosa, Daniel R.
    Wang, Wei-Lien
    Petty, William J.
    Mehta, Kathan
    Faller, Bryan A.
    Agamah, Edem S.
    Kasbari, Samer S.
    Malisetti, Rajini K.
    Kumar, Atul
    Schallenkamp, John
    Alluri, Krishna C.
    Gray, Jhanelle E.
    Kelly, Karen
    JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (03) : 383 - 394
  • [2] Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts).
    Gadgeel, Shirish M.
    Ventimiglia, Jaclyn
    Kalemkerian, Gregory Peter
    Fidler, Mary J.
    Chen, Wei
    Sukari, Ammar
    Halmos, Balazs
    Boerner, Julie
    Wozniak, Antoinette J.
    Galasso, Cathy
    Pennell, Nathan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Phase 2 Study Analysis of Talazoparib (TALA) Plus Temozolomide (TMZ) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    Goldman, J.
    Cummings, A.
    Mendenhall, M.
    Velez, M. A.
    Babu, S.
    Johnson, T.
    Alcantar, J.
    Dakhil, S.
    Kanamori, D.
    Lawler, W.
    Anand, S.
    Chauv, J.
    Garon, E.
    Slamon, D.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S32 - S32
  • [4] Patterns of Disease Progression after Carboplatin/Etoposide plus Atezolizumab in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
    Higgins, K. A.
    Curran, W. J., Jr.
    Liu, S. V.
    Yu, W.
    Brockman, M.
    Johnson, A.
    Bara, I.
    Bradley, J. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (05): : 1398 - 1398
  • [5] Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
    Garcia-Campelo, M. R.
    Domine, M.
    Carpeno, J. De Castro
    Vega, A. L. Moreno
    Aix, S. Ponce
    Arriola, E.
    Carcereny, E.
    Majem, M.
    Vence, G. Huidobro
    Gonzalez, E. Esteban
    Pradera, J. Fuentes
    Granados, A. L. O. Ortega
    Morales, M. Guillot
    Sureda, B. Massuti
    Barragan, P. Lianes
    Calderon, R. Alonso
    Fajardo, C. A.
    Crama, L.
    Laborda, N. Lerones
    Dols, M. Cobo
    ANNALS OF ONCOLOGY, 2023, 34 : S1064 - S1065
  • [6] Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab
    Daniel, D.
    Kuchava, V.
    Bondarenko, I.
    Ivashchuk, O.
    Spigel, D.
    Dasgupta, A.
    Reddy, S.
    Melkadze, T.
    Jaal, J.
    Kudaba, I.
    Hart, L.
    Matitashvili, A.
    Koynov, K. D.
    Yang, Z.
    Wolfe, S. G.
    Malik, R.
    Morris, S. R.
    Antal, J. M.
    Goldschmidt, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 713 - 713
  • [7] A RANDOMIZED PHASE II STUDY OF CARBOPLATIN AND ABRAXANE WITH TWO DIFFERENT SCHEDULES, IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
    Grilley-Olson, Juneko
    Keedy, Vicki L.
    Sandler, Alan
    Socinski, Mark A.
    Moore, Dominic T.
    Stinchcombe, Thomas
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1350 - S1351
  • [8] Financial toxicity of front-line platinum etoposide plus atezolizumab versus durvalumab in extensive-stage small-cell (ES-SCLC) lung cancer.
    Harrison, Bradley
    Keith, Nicole
    Verbyla, Allison
    Mileham, Kathryn Finch
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 23 - 23
  • [9] A randomized phase II trial of pemetrexed (P) plus cisplatin (cis) or carboplatin (carbo) in extensive stage small cell lung cancer (ES-SCLC)
    Socinski, M
    Weissman, C
    Hart, L
    Beck, J
    Choksi, J
    Hanson, J
    Prager, D
    Bloss, L
    Ze, Y
    Obasaju, C
    LUNG CANCER, 2005, 49 : S328 - S329
  • [10] A randomized phase II trial of pemetrexed (P) plus cisplatin (cis) or carboplatin (carbo) in extensive stage small cell lung cancer (ES-SCLC).
    Socinski, MA
    Weissman, CH
    Hart, LL
    Beck, JT
    Choksi, JK
    Hanson, JP
    Prager, D
    Bloss, LP
    Ye, Z
    Obasaju, CK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 661S - 661S
12345